Advaxis (ADXS) Sets New 1-Year Low at $0.39

Advaxis, Inc. (NASDAQ:ADXS) reached a new 52-week low during mid-day trading on Thursday . The stock traded as low as $0.39 and last traded at $0.39, with a volume of 4862 shares. The stock had previously closed at $0.41.

ADXS has been the topic of several research analyst reports. HC Wainwright reiterated a “buy” rating on shares of Advaxis in a report on Wednesday, September 12th. ValuEngine upgraded Advaxis from a “hold” rating to a “buy” rating in a report on Thursday, November 1st.

The firm has a market capitalization of $20.82 million, a price-to-earnings ratio of -0.16 and a beta of 2.46.

Advaxis (NASDAQ:ADXS) last issued its earnings results on Monday, September 10th. The biotechnology company reported ($0.27) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by ($0.02). The company had revenue of $1.13 million for the quarter, compared to analyst estimates of $1.85 million. Advaxis had a negative return on equity of 165.23% and a negative net margin of 1,062.68%. On average, equities analysts forecast that Advaxis, Inc. will post -1.09 earnings per share for the current fiscal year.

In related news, Director Roni Appel bought 33,333 shares of the stock in a transaction dated Tuesday, September 11th. The shares were acquired at an average cost of $1.20 per share, for a total transaction of $39,999.60. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 7.21% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in ADXS. LMR Partners LLP purchased a new stake in shares of Advaxis during the 2nd quarter valued at approximately $171,000. Paloma Partners Management Co purchased a new stake in shares of Advaxis during the 2nd quarter valued at approximately $265,000. Finally, Renaissance Technologies LLC raised its position in shares of Advaxis by 173.0% during the 3rd quarter. Renaissance Technologies LLC now owns 1,191,846 shares of the biotechnology company’s stock valued at $1,120,000 after buying an additional 755,352 shares during the period. 24.81% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Advaxis (ADXS) Sets New 1-Year Low at $0.39” was originally posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this article on another site, it was illegally copied and republished in violation of United States & international copyright laws. The correct version of this article can be read at

About Advaxis (NASDAQ:ADXS)

Advaxis, Inc, a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based immunotherapies in the United States. It is developing Axalimogene filolisbac and ADXS-Dual that are Lm-LLO immunotherapy product candidates for the treatment of human papilloma virus associated cancers, including cervical, and head and neck cancers.

Featured Article: How to invest in a bear market

Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with's FREE daily email newsletter.

Leave a Reply